Page 1233 - Clinical Immunology_ Principles and Practice ( PDFDrive )

1196 PART TEN Prevention and Therapy of Immunological Diseases

4. Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for 18. DiDonato JA, Mercurio F, Karin M. NF-κB and the link between
STI-571 inhibition of Abelson tyrosine kinase. Science 2000;289:1938–42. inflammation and cancer. Immunol Rev 2012;246:379–400.
5. Adams J, Huang P, Patrick D. A strategy for the design of multiplex 19. Cantrell DA. Phosphoinositide 3-kinase signalling pathways. J Cell Sci
inhibitors for kinase-mediated signalling in angiogenesis. Curr Opin 2001;114:1439–45.
Chem Biol 2002;6:486–92. 20. Camps M, et al. Blockade of PI3Kgamma suppresses joint inflammation
6. Davies TG, Pratt DJ, Endicott JA, et al. Structure-based design of and damage in mouse models of rheumatoid arthritis. Nat Med
cyclin-dependent kinase inhibitors. Pharmacol Ther 2002;93:125–33. 2005;11:936–43.
7. Kantarjian H, et al. Dasatinib versus imatinib in newly diagnosed 21. Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in
chronic-phase chronic myeloid leukemia. N Engl J Med patients with relapsed indolent lymphoma. N Engl J Med
2010;362:2260–70. 2014;370:1008–18.
8. Arai S, et al. A Randomized Phase II Crossover Study of Imatinib or 22. Juntilla MM, Wofford JA, Birnbaum MJ, et al. Akt1 and Akt2 are required
Rituximab for Cutaneous Sclerosis after Hematopoietic Cell for αβ thymocyte survival and differentiation. Proc Natl Acad Sci USA
Transplantation. Clin Cancer Res 2016;22:319–27. 2007;104:12105–10.
9. Ghoreschi K, et al. Modulation of Innate and Adaptive Immune 23. McManus EJ, Alessi DR. TSC1-TSC2: a complex tale of PKB-mediated
Responses by Tofacitinib (CP-690,550). J Immunol 2011;186:4234–43. S6K regulation. Nat Cell Biol 2002;4:E214–16.
10. Fleischmann R, et al. Placebo-controlled trial of tofacitinib monotherapy 24. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with
in rheumatoid arthritis. N Engl J Med 2012;367:495–507. mycophenolate mofetil induction for the prevention of acute graft
11. Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and rejection in renal allograft recipients. Transplantation 2000;69:1252–60.
new strategies for treating autoimmune diseases. Nat Rev Rheumatol 25. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response.
2016;12:25–36. Annu Rev Immunol 2002;20:55–72.
12. Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the 26. Josephs DH, Ross PJ. Sorafenib in hepatocellular carcinoma. Br J Hosp
treatment of myeloproliferative neoplasms and psoriasis. IDrugs Med (Lond) 2010;71:451–6.
2010;13:394–403. 27. Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver
13. Zamoyska R, Basson A, Filby A, et al. The influence of the Src-family inflammation and tumorigenesis by enhancing IL-6 and TNF expression.
kinases, Lck and Fyn, on T cell differentiation, survival and activation. Cell 2010;140:197–208.
Immunol Rev 2003;191:107–18. 28. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and
14. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in cobimetinib in BRAF-mutated melanoma. N Engl J Med
relapsed or refractory mantle-cell lymphoma. N Engl J Med 2014;371:1867–76.
2013;369:507–16. 29. Gum R, Wang H, Lengyel E, et al. Regulation of 92 kDa type IV
15. Calne RY. Organ transplantation has come of age. Sci Prog collagenase expression by the Jun aminoterminal kinase—and the
2010;93:141–50. extracellular signal-regulated kinase-dependent signaling cascades.
16. Zanin-Zhorov A, Ding Y, Kumari S, et al. Protein kinase C-theta Oncogene 1997;14:1481–93.
mediates negative feedback on regulatory T cell function. Science 30. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the
2010;328:372–6. regulation of inflammatory cytokine biosynthesis. Nature
17. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a 1994;372:739–46.
billion or so and call me in the morning. Immunity 2009;30:656–65.